Product Images Fulvestrant
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 17 images provide visual information about the product associated with Fulvestrant NDC 16714-070 by Northstar Rx, Llc,, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
carton-label.jpg - carton label
This is a description of a medication called Fulvestrant Inject, which is available in a package with NDC number 16714-070-02. It is an injection that contains 250 mg of Fulvestrant per 5 ml (50 mg/mL) and is intended for intramuscular use only. The last line of text is not legible.*
Figure-1 - fulvestrant inj fig 1
Figure-10 - fulvestrant inj fig 10
Figure-11 - fulvestrant inj fig 11
This appears to be a chart displaying the Progression-Free Survival Probability for two groups of patients. The first group (N=446) received a combination of FULVESTRANT and Abemaciclib, while the second group (N=223) only received FULVESTRANT plus Placebo. The chart displays the probability of progression-free survival over time in months, with the x-axis displaying time in months and the y-axis displaying the percentage of patients expected to survive progression-free. However, without more context or information it is difficult to interpret the chart fully or what disease or condition was being studied.*
Figure-12 - fulvestrant inj fig 12
The given text is a survival probability chart showing patients who received FULVESTRANT with Abemaciclib and FULVESTRANT with Placebo. The chart is plotted over time in months and shows the number of patients alive in both groups. There were 446 patients who received FULVESTRANT with Abemaciclib and 223 patients who received FULVESTRANT with Placebo. The observations of 100 patients are censored. Censored observations are those patients who were lost to follow-up or did not experience an event within the duration of the study.*
Figure-13 - fulvestrant inj fig 13
Figure-14 - fulvestrant inj fig 14
Figure-2 - fulvestrant inj fig 2
Figure-3 - fulvestrant inj fig 3
Figure-4 - fulvestrant inj fig 4
Figure-5 - fulvestrant inj fig 5
Figure-6 - fulvestrant inj fig 6
This is a survival analysis table showing the number of individuals at risk over time for two different doses of Fulvestrant (a type of medication used to treat breast cancer). However, without information on the event being studied (such as death or disease progression) it is difficult to provide further context.*
Figure-7 - fulvestrant inj fig 7
Figure-8 - fulvestrant inj fig 8
Figure-9 - fulvestrant inj fig 9
Structure - fulvestrant inj structure
container-label.jpg - vial label
This is a description of a medication called Fulvestrant Injection that comes in a 250 mg/5 mL (50 mg/mL) dose, and is for single-use only. The medication should be protected from light and both single-dose prefilled syringes must be used to receive the 500 mg dose. The text also includes information about the manufacturer and lot number of the medication.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.